Literature DB >> 3840630

Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens.

C Brambilla, A Rossi, P Valagussa, G Bonadonna.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3840630     DOI： 10.1007/bf01655188

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  21 in total

1.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

Authors:  B Fisher; P Carbone; S G Economou; R Frelick; A Glass; H Lerner; C Redmond; M Zelen; P Band; D L Katrych; N Wolmark; E R Fisher
Journal:  N Engl J Med       Date:  1975-01-16       Impact factor: 91.245

Review 2.  Adjuvant systemic therapy for resectable breast cancer.

Authors:  G Bonadonna; P Valagussa
Journal:  J Clin Oncol       Date:  1985-02       Impact factor: 44.544

Review 3.  The importance of dose intensity in chemotherapy of metastatic breast cancer.

Authors:  W Hryniuk; H Bush
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

4.  The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival.

Authors:  C Redmond; B Fisher; H S Wieand
Journal:  Cancer Treat Rep       Date:  1983-06

5.  Response and survival in advanced breast cancer after two non-cross-resistant combinations.

Authors:  C Brambilla; M De Lena; A Rossi; P Valagussa; G Bonadonna
Journal:  Br Med J       Date:  1976-04-03

6.  Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.

Authors:  A Howell; H Bush; W D George; J M Howat; D Crowther; R A Sellwood; R D Rubens; J L Hayward; R D Bulbrook; I S Fentiman
Journal:  Lancet       Date:  1984-08-11       Impact factor: 79.321

7.  Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.

Authors:  G Bonadonna; P Valagussa; A Rossi; G Tancini; C Brambilla; M Zambetti; U Veronesi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

8.  Controlled trial of adjuvant chemotherapy with melphalan for breast cancer.

Authors:  R D Rubens; J L Hayward; R K Knight; R D Bulbrook; I S Fentiman; M Chaudary; A Howell; H Bush; D Crowther; R A Sellwood; W D George; J M Howat
Journal:  Lancet       Date:  1983-04-16       Impact factor: 79.321

9.  Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.

Authors:  S G Taylor; L A Kalish; J E Olson; F Cummings; J M Bennett; G Falkson; D C Tormey; P P Carbone
Journal:  J Clin Oncol       Date:  1985-02       Impact factor: 44.544

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
View more
  1 in total

1.  Adjuvant CMF chemotherapy in operable breast cancer: ten years later.

Authors:  G Bonadonna; A Rossi; P Valagussa
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.